MedTrace Logo

NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma

NCT07114367 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-01-30

No results posted yet for this study

Summary

This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL

Conditions

  • Non Hodgkin Lymphoma (NHL)

Interventions

DRUG

NB02 (Poseltinib)

Dose Level 1, Dose Level 2, Dose Level 3

Sponsors & Collaborators

  • NOBO Medicine

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-02
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07114367 on ClinicalTrials.gov